Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Phase 1

• Conditions: Acute Myeloid Leukemia
• Interventions: Biological: Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

• Registration Number: NCT03222674
• Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Brief Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Detailed Description

Acute myeloid leukemia (AML) is a malignant disease characterized by the rapid growth of myeloblasts that build up in the bone marrow and interfere with the production of normal blood cells.

In this study, the patients' own T cells will be genetically modified with lentiviral vectors expressing chimeric antigen receptors. The multi-CAR T cells recognize specific molecules such as CD33, CD38, CD123, CD56, MucI, and CLL1, which are often found expressed on the surface of AML cells. The engineered CAR T cells will be infused into patients.

The purpose of this clinical study is to assess the feasibility, safety and efficacy of the multi-CAR T cell therapy against AML. Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Study Timeline

• Study First Submitted: 2017-07-14
• Study Start: 2017-07-15
• Study First Submitted QC: 2017-07-17
• Study First Posted: 2017-07-19
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-15
• Last Update Posted: 2018-10-17
• Primary Completion: 2019-12-31
• Study Completion: 2020-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Age older than 2 years.
2. CD33, CD38, CD56, CD123, MucI, and CLL1 expression can be identified in the malignant cells by immuno-histochemical staining or flow cytometry.
3. Karnofsky performance status (KPS) score is higher than 80 and life expectancy > 2 months.
4. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dL.
5. Hgb≥80g/L.
6. No cell separation contraindications.
7. Abilities to understand and the willingness to provide written informed consent.

Read More

Exclusion Criteria

1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.
2. Active bacterial, fungal or viral infection not controlled by adequate treatment.
3. Known HIV or hepatitis B virus (HBV) infection.
4. Pregnant or nursing women may not participate.
5. History of glucocorticoid for systemic therapy within the week prior to entering the test.
6. Previously treatment with any gene therapy products.
7. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single arm	Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells	CAR T cells to treat AML

Primary Outcome Measures

Name	Time	Method
percentage of patients with treatment related adverse effect	a year	percentage of participants with treatment-related adverse events, as assessed by physical exam, vital signs, standard clinical labs and so on.

Secondary Outcome Measures

Name	Time	Method
Anti tumor activity of fourth generation CAR-T cells in patients with relapsed or refractory AML	a year	scale of CAR copies and leukemic cell burden (for efficacy)

Trial Locations

Locations (3)

Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center; 🇨🇳 KunMing, Yunnan, China

Zhujiang Hospital of Southern Medical University; 🇨🇳 Guangzhou, Guangdong, China

Shenzhen Geno-immune Medical Institute; 🇨🇳 Shenzhen, Guangdong, China